novartis.usNovartis United States of America

Skip to main navigation Skip to main content Skip to Footer Google Tag Manager US Novartis site directory Our Products US Products By Brand Patient Assistance Product Portfolio Our Process Therapeutic Areas Product Related Issues About Us Novartis US at a Glance Who We Are Diversity & Inclusion Our Leadership Research Contact Us Corporate Responsibility Novartis in Society US Reports External Funding Corporate Citizenship Business Conduct Corporate Integrity Agreement Payments to HCPs & HCOs Post-Marketing Commitments Enhanced Verification Request News News Archive Statements Stories US Media Contacts Novartis US COVID-19 Initiatives Careers Careers Search Working at Novartis Employee Benefits Awards & Recognition NIBR Careers Frequently Asked Questions Search index At Novartis, we are reimagining medicine Novartis Financial Results – Q1 2021 Novartis announced the company’s financial results for the first quarter of 2021. Read More Building clinical trial diversity for long-term equity Vas Narasimhan reflects on how to increase diversity in clinical trials. Read More COVID-19 US Information Center Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources. Enter Novartis in Society 2020 US Report Novartis is striving every day to help patients, strengthen communities, drive sustainability, and build a more equitable and responsive healthcare system for all. Read More Notice to Healthcare Providers and Entities Novartis enters into Corporate Integrity Agreement with Office of Inspector General (OIG) of the US Department of Health & Human Services. Read More Novartis US at a Glance Learn more about Novartis in the US and our impact on patients, families and their communities. Read More Latest News Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™ Media releases AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy Learn More Standing for Racial Equity and Justice as One Novartis We believe unequivocally that Black Lives Matter. As a company focused on improving human health globally, we also recognize the disparities Black communities and communities of color face when it comes to healthcare. Read More Novartis United States Our Products About Us News Careers Contact Us Corporate Responsibility Locations Subscribe to Novartis Facebook Twitter YouTube LinkedIn Instagram Novartis Site Directory © 2021 Novartis Pharmaceuticals Corporation This site is intended for US Residents Only Terms of Use Privacy Policy About Cookies...